

Appendix D. Extraction Forms

General Data Extraction Form

1. Which peptide was assessed?

- e.g. BNP
- e.g. NT-proBNP
- e.g. Both

2. In what country was the study conducted or administrated?

Please specify the country where the study was conducted. Note that in some papers only the city/province will be reported, e.g. Copenhagen. In such case, please choose “Others” and report the city’s name. For countries not listed in the drop-down option, please choose “Others” and specify.

3. What was the study type?

Please specify study type. Note that the provided list may not contain all the study types, but these are the most common. You may also refer to “Study Design Descriptions” for definition.

4. What is the total number of patients included in the study?

Please report all that apply.

Total # enrolled (n) = *Total number of subjects who meet the inclusion criteria of the study/randomized.*

Total treatment (n) (e.g. “n” of index group) = *Total number of patients in each group who are randomized into the BNP/NT-proBNP or clinical intervention.*

Total control (n) (e.g. “n” of reference group) = *Total number of patient who are receiving receiving usual care/standard care/clinical group.*

- Example = 500 patients are enrolled in the study, but only 450 meets the inclusion criteria. After randomization, 225 receives BNP-guided treatment, while 225 receives usual-care. Therefore:

Total # enrolled (n) = 450

Total treatment (n) (e.g. “n” of index group) = 225

Total control (n) (e.g. “n” of reference group) = 225

5. Please report the AGE CHARACTERISTICS for:

Please record as reported.

6. Please report the AGE GROUPS, if applicable:

If the study reported the group age as, e.g. ≤ 50 yrs or ≥ 50 yrs, please report the sign as ≤ 50 yrs or ≥ 50 yrs.

7. Please report GENDER:

Please record as reported.

8. Please report Race/Ethnicity:

Please record as reported.

9. Please describe the population included in the study:

Please record as reported the population characteristics.

10. Please describe the following outcomes/end-points:

Primary outcome/end-points: *The primary outcome that is measured to see if a given treatment worked (e.g., the number of all-cause mortality, number of hospitalization).*

Secondary outcome/end-points: *Other outcomes reported in the study.*

11. What other medical conditions (co-morbidities) did the patients have? (Check and record all that apply)

Please record as reported.

12. Which test was used to measure BNP or/and NT-proBNP

Please record as reported.

13. List and report (n,%) the adverse events associated with BNP/NT-proBNP testing reported?

Please record as reported. E.g. Hypotension, renal failure, etc.